These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17457227)

  • 1. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
    Danesi R; Pasqualetti G; Giovannetti E; Del Tacca M
    J Thorac Oncol; 2007 May; 2(5 Suppl):S27-30. PubMed ID: 17457227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
    Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
    Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward therapies tailored to patient characteristics.
    Novello S; Longo M; Levra MG
    J Thorac Oncol; 2007 May; 2(5 Suppl):S38-41. PubMed ID: 17457231
    [No Abstract]   [Full Text] [Related]  

  • 5. On the pharmacogenetics of non-small cell lung cancer treatment.
    Santarpia M; Rolfo C; Peters GJ; Leon LG; Giovannetti E
    Expert Opin Drug Metab Toxicol; 2016; 12(3):307-17. PubMed ID: 26761638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
    Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
    Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adjuvant chemotherapy in NSCLC (stages I to III).
    Coleman MH; Bueno R
    Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
    Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
    Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Substantiation of Expressive Markers Use to Personalize Lung Cancer Chemotherapy].
    Tsyganov MM; Rodionov EO; Miller SV; Litvyakov NV
    Antibiot Khimioter; 2015; 60(9-10):38-45. PubMed ID: 27141638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
    Chetty C; Rao JS; Lakka SS
    Pharmacogenomics; 2011 Apr; 12(4):535-46. PubMed ID: 21521025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
    d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
    Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
    Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Del Tacca M; Danesi R
    Mol Cancer Ther; 2006 Jun; 5(6):1387-95. PubMed ID: 16818496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
    Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy and the role of chemotherapy resistance testing for stage I non-small cell lung cancer.
    D'Amato TA
    Thorac Surg Clin; 2007 May; 17(2):287-99. PubMed ID: 17626407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in chemotherapy of non-small cell lung cancer.
    Molina JR; Adjei AA; Jett JR
    Chest; 2006 Oct; 130(4):1211-9. PubMed ID: 17035458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future options for ALK-positive non-small cell lung cancer.
    Iacono D; Chiari R; Metro G; Bennati C; Bellezza G; Cenci M; Ricciuti B; Sidoni A; Baglivo S; Minotti V; Crinò L
    Lung Cancer; 2015 Mar; 87(3):211-9. PubMed ID: 25601484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.
    Carbone DP; Felip E
    Clin Lung Cancer; 2011 Sep; 12(5):261-71. PubMed ID: 21831720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.